Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
Using regionally delivered autologous mesothelin-targeted CAR T cells in the treatment of malignant pleural disease

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 474

Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA

Dr Prasad Adusumilli speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about the results from a phase I clinical trial that assessed the safety and efficacy of using regionally delivered autologous mesothelin-targeted CAR T cells to treat malignant pleural disease.

Dr Adusumilli explains the premise of the study - in which the success of CAR T cell therapy in the treatment of solid tumours remains limited.

By creating a second-generation mesothelin-targeted CAR, these agents were administered intravenously to patients with mesothelin-expressing, malignant pleural disease in a dose-escalating clinical trial.

Dr Adusumilli reports that off-target toxicity was not observed in patients during treatment and that a cohort of patients were also given anti-PD1 therapy.

Using this combined therapy approach, a response rate of 72 percent was achieved, with some patients not requiring any additional treatment for up to a year.

He states that these results are encouraging and plans to establish the long- term safety and efficacy of this type of therapy in further clinical trials.

Read more about this research here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation